This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Incandela, L. Articles by Acerbi, G. Search for Related Content PubMed PubMed Citation Articles by Incandela, L. Articles by Acerbi, G. Social Bookmarking                         What's this?

HR (Paroven, Venoruton; 0-(ß-hydroxyethyl)-rutosides) in Venous Hypertensive Microangiopathy: A Prospective, Placebo-Controlled, Randomized Trial

G. Belcaro, MD, PhD

S. Renton, MD

M. T. DeSanctis, MD

M. R. Cesarone, MD

P. Bavera, MD

E. Ippolito, MD

M. Bucci, MD

M. Griffin, PhD

G. Geroulakos, PhD

M. Dugall, MD

G. Golden, MD

G. Acerbi, MD

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy; Irvine Vasc Lab, St Mary's Hospital, Imperial College; Vascular Unit, Ealing Hospital, London, UK.

The aim of this study was to demonstrate whether HR (Paroven-Venoruton; 0-(ß-hydroxyethyl)-rutosides), was effective in improving the microcirculation in venous hypertension and microangiopathy. Sixty patients with severe venous hypertension due to chronic venous insufficiency, ankle swelling, and lipodermatosclerosis were included. After informed consent, patients were randomized into a treatment group and a placebo group. Patients in the treatment group received oral HR (2 g/day for 8 weeks); those in the placebo group received a comparable placebo.

Results: The two groups were comparable for age and sex distribution. The mean age was 45 years (SD 9) in the treatment group (31 patients) and 45.5 (SD 10) in the placebo group (29 patients). There were no differences between the placebo and treatment groups at inclusion. There was no change between inclusion and measurements at 8 weeks in the placebo group. A significant decrease (P < 0.05) in flux at rest and rate of ankle swelling was observed in the treatment group. The decrease in capillary filtration was associated with improvement in signs and symptoms (P < 0.05). The difference in flux, sign and symptoms, and filtration was clinically important at 8 weeks in the treatment group when compared with the placebo group. No adverse effects were observed.

Conclusion: Venous microangiopathy was improved by HR treatment.

Key Words: venous disease • varicose veins • ulcerations • hr • Paroven • Venoruton 0-(ß-hydroxyethyl)-rutosides) • elastic compression • edema • veins • microangiopathy

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 7, No. 1 suppl, S7-S10 (2002)
DOI: 10.1177/107424840200700103


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Belcaro, M. Rosaria Cesarone, A. Ledda, M. Cacchio, I. Ruffini, A. Ricci, E. Ippolito, A. Di Renzo, M. Dugall, M. Corsi, et al. O-({beta}-Hydroxyethyl)-Rutosides Systemic and Local Treatment in Chronic Venous Disease and Microangiopathy: An Independent Prospective Comparative Study Angiology, March 1, 2008; 59(1_suppl): 7S - 13S. [Abstract] [PDF]

				G. Belcaro, M. R. Cesarone, A. Ledda, M. Cacchio, I. Ruffini, A. Ricci, E. Ippolito, A. Di Renzo, M. Dugall, M. Corsi, et al. 5-Year Control and Treatment of Edema and Increased Capillary Filtration in Venous Hypertension and Diabetic Microangiopathy Using O-({beta}-Hydroxyethyl)-Rutosides: A Prospective Comparative Clinical Registry Angiology, March 1, 2008; 59(1_suppl): 14S - 20S. [Abstract] [PDF]

				U. Wollina, M. B. Abdel-Naser, and R. Mani A Review of the Microcirculation in Skin in Patients With Chronic Venous Insufficiency: The Problem and the Evidence Available for Therapeutic Options International Journal of Lower Extremity Wounds, September 1, 2006; 5(3): 169 - 180. [Abstract] [PDF]

				M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, G. Vinciguerra, A. Ricci, A. Di Renzo, I. Ruffini, G. Gizzi, E. Ippolito, et al. Venoruton(R) vs Daflon(R): Evaluation of Effects on Quality of Life in Chronic Venous Insufficiency Angiology, March 1, 2006; 57(2): 131 - 138. [Abstract] [PDF]

				M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, G. Vinciguerra, A. Ricci, G. Gizzi, E. Ippolito, F. Fano, M. Dugall, et al. HR, 0-(Beta-Hydroxyethyl)-Rutosides; (Venoruton(R)): Rapid Relief of Signs/Symptoms in Chronic Venous Insufficiency and Microangiopathy: A Prospective, Controlled Study Angiology, March 1, 2005; 56(2): 165 - 172. [Abstract] [PDF]

				M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, A. Di Renzo, G. Vinciguerra, A. Ricci, G. Gizzi, E. Ippolito, F. Fano, et al. HR, 0-(Beta-Hydroxyethyl)-Rutosides, in Comparison with Diosmin+Hesperidin in Chronic Venous Insufficiency and Venous Microangiopathy: An Independent, Prospective, Comparative Registry Study Angiology, January 1, 2005; 56(1): 1 - 8. [Abstract] [PDF]